medigraphic.com
ISSN 1025-0255 (Electronic)

2015, Number 6

Next >>

AMC 2015; 19 (6)

Safety of the treatment with pulmonary surfactant in adults with acute respiratory distress syndrome

Barrese PY, Hidalgo SÁO, Ávila AY, Uranga PR, Díaz CE, Fernández LO

Language: Spanish
References: 20
Page: 551-558
PDF size: 552.38 Kb.


ABSTRACT

Introduction: acute respiratory distress syndrome is a nosologic disease associated to a high mortality and morbidity.
Objective: to determine the adverse events associated to the therapy with pulmonary surfactant (SURFACEN®) in adults with acute respiratory distress syndrome.
Methods: a randomized and multicentric clinical trial stage II was conducted in 48 adult patients between 18 and 75 years old. The group A, that included 24 patients, received doses of 100 total milligrams of pulmonary surfactant every eight hours for three days, along with the standard treatment (oxygenation and mechanical ventilation). The group B, also with 24 patients, received the standard treatment. The appearance of adverse events was identified and quantified, as well as the seriousness and the causality regarding the medicine from the inclusion of the patient in the study to the discharge from the intensive care unit.
Results: the 56, 25 % of the patients included in the study presented an adverse event: 14 (29, 17 %) in the group A and 13 (27, 08 %) in the group B. The 42, 37 % of these adverse events appeared with moderate intensity; the 39, 39 % were reversible and the 92, 59 % had a remote causality regarding the surfactant. Fever was the most frequent adverse event reported.
Conclusions: pulmonary surfactant, along with the standard treatment in adults with acute res-piratory distress syndrome, is safe.


REFERENCES

  1. Villar Hernández J, Slutsky AS. Is acute respir-atory distress syndrome an iatrogenic disease? Crit Care. 2010;14:120.

  2. Morales MMB, Pires-Neto RC, Inforsato N, Lanças T, Silva LFF da, Saldiva PHN, et al. Small airway remodeling in acute respirato-ry distress syndrome: a study in autopsy lung tissue. Critical Care. 2011;15:R4.

  3. Hodgson CL, Tuxen DV, Davies AR, Bailey MJ, Higgins AM, Holland AE, et al. A randomised controlled trial of an open lung strategy with staircase recruitment, titrated PEEP and targeted low airway pressures in patients with acute respiratory distress syndrome. Critical Care. 2011;15:R133.

  4. Charron C, Repesse X, Bouferrache K, Bod-son L, Castro S, Page B, et al. PaCO2 and al-veolar dead space are more relevant than PaO2/FiO2 ratio in monitoring the respiratory response to prone position in ARDS patients: a physiological study. Critical Care. 2011;15:R175.

  5. Carlos A. De Villegas Córdova. Manejo del daño pulmonar agudo y del síndrome de dificultad respiratoria aguda. Rev Bol Ped. 2010;49(3):45-62.

  6. Amital A, Shitrit D, Raviv Y, Saute M, Medalion B, Bakai L, et al. The use of surfactant in lung transplantation. Transplantation. 2008;86(11):1554-9.

  7. Raghavendran K, Willson D, Notter RH. Surfac-tant Therapy of ALI and ARDS. Crit Care Clin. 2011;27:525-59.

  8. Zhang LN, Sun JP, Xue XY, Wang JX. Exoge-nous pulmonary surfactant for acute respirato-ry distress syndrome in adults: A systematic review and meta-analysis. Exp Ther Med. 2013 Jan;5(1):237-42.

  9. Spragg RG, Lewis JF, Walmrath H-D, Johan-nigman J, Bellingan G, Laterre P-F, et al. Effect of Recombinant Surfactant Protein C-Based Surfactant on the Acute Respiratory Distress Syndrome. N Engl J Med. 2004 Aug;351:884-92.

  10. Arancibia Hernández F, Soto Figueroa R. Daño pulmonar inducido por la ventilación mecánica. Rev Chilena Med Int. 2010;25(4):205-10.

  11. Bosch Costafreda C, Riera Santiesteban R, Ba-dell Pomar C. Morbilidad y mortalidad en pa-cientes con ventilación mecánica invasiva en una unidad de cuidados intensivos. MEDISAN. Mar 2014;18(3):56-61.

  12. Burns KEA, Adhikari NKJ, Slutsky AS, Guyatt GH, Villar J, Zhang H, et al. Pressure and Vol-ume Limited Ventilation for the Ventilatory Management of Patients with Acute Lung Inju-ry: A Systematic Review and Meta-Analysis. PLOS one. 2011 Jan 28;12(1):23-30.

  13. Morilla Guzmán A, Machado Lubián MC, Fer-nández Limia O, Díaz Casañas E, Martín Esté-vez AI. Efectividad de SURFACEN en el trata-miento del síndrome de dificultad respiratoria del recién nacido pretérmino. Rev Cub Med Int Emerg. 2013 Abr 12;(número especial):54-61.

  14. Bernard GR, Artigas A, Brigham KL, Carlet J, Falke K, Hudson L, et al. The American-European Consensus Conference on ARDS. Definitions, mechanisms, relevant outcomes, and clinical trial coordination. Am J Respir Crit Care Med. 1994 Mar; 149 (3 Pt 1):818-24.

  15. Sánchez Rámirez C, Torres Torretti J. Surfac-tante pulmonar. Rev Ped Elec. 2004;1(1):15-20.

  16. Mikkelsen ME, Shah CV, Meyer NJ, Gaieski DF, Lyon S, Miltiades AN, et al. The epidemiology of acute respiratory distress syndrome in pa-tients presenting to the emergency department with severe sepsis. Shock. 2013 Nov;40(5):375-81.

  17. Briegel I, Dolch M, Irlbeck M, Hauer D, Kaufmann I, Schelling G. Quality of results of therapy of acute respiratory failure: changes over a period of two decades. Anaesthe-sist. 2013 Apr;62(4):261-70.

  18. Tomicic V, Fuentealba A, Martínez E, Graf J, Batista Borges J. The basics on mechanical ventilation support in acute respiratory distress syndrome. Med Int. 2010 Ago-Sep;34(6):25-32.

  19. Mok YH, Lee JH, Rehder KJ, Turner DA. Adjun-tive treatments in pediatric acute respiratory distress syndrome. Expert Rev Respir Med. 2014 Aug;13:1-14.

  20. Tonelli AR, Zein J, Adams J, Ioannidis JPA. Effects of interventions on survival in acute respiratory distress syndrome: an umbrella review of 159 published randomized trials and 29 meta-analyses.




2020     |     www.medigraphic.com